https://www.businesswire.com/news/home/20221113005163/en/GICELL-Announces-the-Preclinical-Research-Data-Demonstrating-the-Superiority-of-the-NK-Cell-Mass-Culture-Platform-at-the-Society-for-Immunotherapy-of-Cancer
GICELL Announces the Preclinical Research Data Demonstrating the Superiority of the NK Cell Mass...
GICELL announced the data from the preclinical studies on T.O.P. NK therapy at the Society for Immunotherapy of Cancer that was held in Boston.
preclinical research